Baxter International Inc vs Innodata Inc — how do they compare? Baxter International Inc trades at $27.08 (market cap $14.27B), while Innodata Inc trades at $61.38 (market cap $2.05B). The key difference: Baxter International Inc is far larger — about 7× Innodata Inc's market cap, and Baxter International Inc pays a 0.14% dividend while Innodata Inc pays none. Which is the better fit depends on your goals.
| BAX | INOD | |
|---|---|---|
Market Cap | $14.27B | $2.05B |
Sector | Health | Technology |
52-Week High | $28.35 | $121.50 |
52-Week Low | $15.80 | $34.45 |
Enterprise Value | $21.79B | $1.80B |
Dividend Yield | 0.14% | — |
Signals from Pluang's Aura AI — not financial advice
Baxter International (BAX) trades at $27.22, down 2.02% today, with a bullish technical signal and strong recent earnings beats. The company reported Q2 2026 EPS of $0.56, beating expectations of $0.3665, and raised full-year guidance. Despite negative net income margins and high P/E of 87.85, cash flow trends improved with 2026 net cash flow projected at $468 million. Recent news highlights a 7.4% surge on August 3, 2026, following positive quarterly results and a cash tender offer announcement.
The outlook is cautiously optimistic due to earnings momentum and raised guidance, but high valuation and persistent negative profitability pose risks. Analyst consensus is mixed with 41.67% buy ratings, a $25.43 price target, and institutional activity showing volatility. Key risks include margin pressures and debt levels, though operational improvements may support recovery.
INOD trades at $62.26, up 0.06% on the day, with a bullish technical signal supported by oscillators and strong momentum indicators. The company reported robust Q2 2026 results, beating EPS estimates with $0.41 versus $0.21 expected, driven by 58% revenue growth and margin expansion. Analyst consensus is bullish with a $130 price target, reflecting optimism around AI-driven growth and profitability improvements.
Outlook remains positive due to accelerating AI demand and operational leverage, though the stock's premium valuation (P/E 48.62) poses a risk if growth moderates. Key opportunities include continued AI adoption and customer diversification, while risks involve execution challenges and competitive pressures in the AI services sector.
Trailing returns across standard periods
Baxter offers a variety of medical instruments and supplies to caregivers. It enhanced its portfolio of hospital-focused offerings by acquiring Hillrom in late 2021. Legacy Baxter offers tools to help patients with acute and chronic kidney failure. It also sells a variety of injectable therapies for use in care settings, such as IV pumps, and administrative sets.
Read more on BAX →Innodata is a global data engineering company that provides solutions for training AI models. It helps enterprises solve complex data challenges through high-quality data annotation and digital transformation.
Read more on INOD →